JP2022011833A - 評価システム、学習装置、予測装置、評価方法、及びプログラム - Google Patents
評価システム、学習装置、予測装置、評価方法、及びプログラム Download PDFInfo
- Publication number
- JP2022011833A JP2022011833A JP2020113218A JP2020113218A JP2022011833A JP 2022011833 A JP2022011833 A JP 2022011833A JP 2020113218 A JP2020113218 A JP 2020113218A JP 2020113218 A JP2020113218 A JP 2020113218A JP 2022011833 A JP2022011833 A JP 2022011833A
- Authority
- JP
- Japan
- Prior art keywords
- information
- cancer
- drug
- learning
- anticancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000013016 learning Effects 0.000 title claims abstract description 209
- 238000011156 evaluation Methods 0.000 title claims abstract description 93
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 285
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 212
- 201000011510 cancer Diseases 0.000 claims abstract description 203
- 230000001093 anti-cancer Effects 0.000 claims abstract description 106
- 230000000694 effects Effects 0.000 claims abstract description 55
- 238000011282 treatment Methods 0.000 claims abstract description 37
- 210000004027 cell Anatomy 0.000 claims description 299
- 229940041181 antineoplastic drug Drugs 0.000 claims description 206
- 229940079593 drug Drugs 0.000 claims description 152
- 239000003814 drug Substances 0.000 claims description 152
- 238000003860 storage Methods 0.000 claims description 39
- 230000006870 function Effects 0.000 claims description 12
- 210000002950 fibroblast Anatomy 0.000 claims description 7
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 4
- 239000003560 cancer drug Substances 0.000 claims description 2
- 230000000857 drug effect Effects 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 description 28
- 238000012805 post-processing Methods 0.000 description 25
- 238000000034 method Methods 0.000 description 23
- 238000007781 pre-processing Methods 0.000 description 23
- 238000004891 communication Methods 0.000 description 21
- 238000012545 processing Methods 0.000 description 15
- 238000010586 diagram Methods 0.000 description 12
- 230000002792 vascular Effects 0.000 description 11
- 210000002889 endothelial cell Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000036737 immune function Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000004037 angiogenesis inhibitor Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000001647 drug administration Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 210000002536 stromal cell Anatomy 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000013527 convolutional neural network Methods 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000890 drug combination Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000005907 cancer growth Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002060 circadian Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 2
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 108010081667 aflibercept Proteins 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000013473 artificial intelligence Methods 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000235 effect on cancer Effects 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 201000006866 hypopharynx cancer Diseases 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002705 metabolomic analysis Methods 0.000 description 2
- 230000001431 metabolomic effect Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000007785 strong electrolyte Substances 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 238000012706 support-vector machine Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- GTXSRFUZSLTDFX-HRCADAONSA-N (2s)-n-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2s)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O GTXSRFUZSLTDFX-HRCADAONSA-N 0.000 description 1
- JRMGHBVACUJCRP-BTJKTKAUSA-N (z)-but-2-enedioic acid;4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 JRMGHBVACUJCRP-BTJKTKAUSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101001065614 Bos taurus Lumican Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 102100039396 C-X-C motif chemokine 16 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101150015280 Cel gene Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 description 1
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 206010061825 Duodenal neoplasm Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 102100020997 Fractalkine Human genes 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 102100031351 Galectin-9 Human genes 0.000 description 1
- 101710121810 Galectin-9 Proteins 0.000 description 1
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N Gimeracil Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 1
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 1
- 101000889133 Homo sapiens C-X-C motif chemokine 16 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 206010071119 Hormone-dependent prostate cancer Diseases 0.000 description 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000005450 Maxillary Sinus Neoplasms Diseases 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- AEULIVPVIDOLIN-UHFFFAOYSA-N cep-11981 Chemical compound C1=C2C3=C4CNC(=O)C4=C4C5=CN(C)N=C5CCC4=C3N(CC(C)C)C2=CC=C1NC1=NC=CC=N1 AEULIVPVIDOLIN-UHFFFAOYSA-N 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000006392 childhood kidney cancer Diseases 0.000 description 1
- 208000013549 childhood kidney neoplasm Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 229940094517 chondroitin 4-sulfate Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 description 1
- 229950009003 cilengitide Drugs 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013135 deep learning Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 108010040063 dermatan sulfate proteoglycan Proteins 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 201000000312 duodenum cancer Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002603 extrahepatic bile duct Anatomy 0.000 description 1
- 229940051306 eylea Drugs 0.000 description 1
- 108060002895 fibrillin Proteins 0.000 description 1
- 102000013370 fibrillin Human genes 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229950009822 gimeracil Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- -1 hormonal agents Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940005319 inlyta Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 229950003968 motesanib Drugs 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000023833 nerve sheath neoplasm Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940015847 ofev Drugs 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 229940005642 polystyrene sulfonic acid Drugs 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 108091008020 response regulators Proteins 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 208000037968 sinus cancer Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000035736 spondylodysplastic type Ehlers-Danlos syndrome Diseases 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 108010075758 trebananib Proteins 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
- G06N3/08—Learning methods
- G06N3/09—Supervised learning
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N20/00—Machine learning
- G06N20/10—Machine learning using kernel methods, e.g. support vector machines [SVM]
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
- G06N3/04—Architecture, e.g. interconnection topology
- G06N3/0464—Convolutional networks [CNN, ConvNet]
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
- G06N3/08—Learning methods
- G06N3/084—Backpropagation, e.g. using gradient descent
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N5/00—Computing arrangements using knowledge-based models
- G06N5/01—Dynamic search techniques; Heuristics; Dynamic trees; Branch-and-bound
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N7/00—Computing arrangements based on specific mathematical models
- G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
Landscapes
- Engineering & Computer Science (AREA)
- Theoretical Computer Science (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Data Mining & Analysis (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Software Systems (AREA)
- Evolutionary Computation (AREA)
- Biomedical Technology (AREA)
- Mathematical Physics (AREA)
- General Engineering & Computer Science (AREA)
- Computing Systems (AREA)
- Artificial Intelligence (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Computational Linguistics (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Probability & Statistics with Applications (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Algebra (AREA)
- Computational Mathematics (AREA)
- Mathematical Analysis (AREA)
- Mathematical Optimization (AREA)
- Pure & Applied Mathematics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
(2)対象者のがん細胞が、投与した抗がん剤に耐性を獲得する可能性
(3)(2)の耐性を獲得したがん細胞に、別の抗がん剤を投与した場合における当該別の抗がん剤による抗がん効果の程度
(4)対象薬剤が、がん細胞に有効に作用する可能性
(5)対象薬剤が有効に作用する可能性がある患者
(6)対象薬剤が有効に作用する可能性があるがん種
(7)対象薬剤を組合せることによる抗がん効果の程度
入力情報取得部730は、予測対象取得部731によって取得された予測対象に応じた入力情報を取得する。入力情報は、予測モデルに入力される情報である。入力情報取得部730は、予測対象(1)が予測する対象である場合、入力情報として、対象者情報720を取得する。入力情報取得部730は、取得した対象者情報720を前処理部732に出力する。
入力情報取得部730、前処理部732、予測部733、および後処理部734が行う処理の流れは、予測対象(1)を予測する場合と同様であるため、その説明を省略する。以下では、予測対象(2)を予測する場合において、予測対象(1)を予測する場合と異なる構成のみを説明する。
入力情報取得部730、前処理部732、予測部733、および後処理部734が行う処理の流れは、予測対象(1)を予測する場合と同様であるため、その説明を省略する。以下では、予測対象(3)を予測する場合において、予測対象(1)を予測する場合と異なる構成のみを説明する。
10…撮像装置
20…判定装置
30…患者情報DB
40…薬剤情報DB
50…評価システム
60…学習装置
61…通信部
62…記憶部
620…状態情報
621…オミクス情報
622…薬剤情報
623…投与実績情報
624…薬剤有効性情報
625…予測モデル情報
63…制御部
630…学習情報取得部
631…前処理部
632…学習部
633…装置制御部
70…予測装置
71…通信部
72…記憶部
720…対象者情報
721…対象薬剤情報
722…予測モデル情報
73…制御部
730…入力情報取得部
731…予測対象取得部
732…前処理部
733…予測部
734…後処理部
735…装置制御部
Claims (16)
- 抗がん効果を評価する評価システムであって、
不特定の被験者におけるがんに関する情報であって、少なくとも不特定の被験者におけるがんの状態を示す状態情報を含む学習データと、前記被験者から採取された細胞に抗がん剤を投与することにより得られる前記抗がん剤の効果に関する情報である教師データとを取得する学習情報取得部と、
前記学習情報取得部により取得された学習データ及び前記教師データの対応関係を、学習モデルに教師あり学習させることにより、抗がん剤を用いた治療に関する予測を行う予測モデルを生成する学習部と、
前記学習部により生成された予測モデルを記憶する記憶部と、
予測する対象とする対象者におけるがんに関する情報である入力情報を取得する入力情報取得部と、
前記入力情報と前記予測モデルとを用いて、抗がん剤を用いた治療に関する予測を行う予測部と、
を備え、
前記学習情報取得部は、不特定の被験者から採取されたがん細胞と、間質を構成する細胞とを含む立体的細胞構造体に抗がん剤を投与することにより得られる、抗がん効果に関する情報を、教師データとして取得する、
評価システム。 - 前記間質を構成する細胞は、線維芽細胞を含む、
請求項1に記載の評価システム。 - 前記間質を構成する細胞は、血管内皮細胞を更に含む、
請求項1又は請求項2に記載の評価システム。 - 前記学習情報取得部は、不特定の被験者におけるがんの状態を示す状態情報、前記被験者から採取された細胞のオミクス情報、抗がん剤に関する薬剤情報、前記立体的細胞構造体に投与した抗がん剤に関する投与実績情報を学習データとして取得し、前記立体的細胞構造体に投与した抗がん剤が有効か否かを判定した結果である薬剤有効性情報を教師データとして取得し、
前記学習部は、がん患者における前記状態情報、前記がん患者から採取された細胞のオミクス情報に基づいて、前記がん患者のがん細胞に作用する抗がん剤の効果を予測する予測モデルを生成する、
請求項1から請求項3のいずれか一項に記載の評価システム。 - 前記入力情報取得部は、予測する対象とする対象者に関する前記状態情報および前記対象者から採取された細胞のオミクス情報を含む対象者情報を、前記入力情報として取得し、
前記予測部は、前記対象者のがん細胞に作用する抗がん剤の効果を予測する、
請求項4に記載の評価システム。 - 前記入力情報取得部は、予測する対象とする抗がん剤に関する対象薬剤情報を前記入力情報として取得し、
前記予測部は、前記対象薬剤情報により特定される抗がん剤が、がん細胞に作用する効果を予測する、
請求項4に記載の評価システム。 - 前記入力情報取得部は、予測する対象とする抗がん剤に関する対象薬剤情報を前記入力情報として取得し、
前記予測部は、前記対象薬剤情報により特定される抗がん剤が、がん細胞に作用する効果を、患者におけるがんの状態ごとに予測する、
請求項4に記載の評価システム。 - 前記状態情報には、前記被験者におけるがんの種類を示す情報が含まれ、
前記入力情報取得部は、予測する対象とする抗がん剤に関する対象薬剤情報を前記入力情報として取得し、
前記予測部は、前記対象薬剤情報により特定される抗がん剤ががん細胞に作用する効果を、がんの種類ごとに予測する、
請求項4に記載の評価システム。 - 前記投与実績情報には、前記立体的細胞構造体に投与した複数の抗がん剤の組合せに関する情報が含まれ、
前記薬剤有効性情報には、前記立体的細胞構造体に投与した前記複数の抗がん剤の組合せにおける抗がん効果を判定した結果が含まれ、
前記入力情報取得部は、予測する対象とする複数の抗がん剤を組み合わせに対応する対象薬剤情報を前記入力情報として取得し、
前記予測部は、前記対象薬剤情報により特定される抗がん剤の組合せが、前記対象者のがん細胞に作用する効果を予測する、
請求項4に記載の評価システム。 - 前記薬剤有効性情報には、前記被験者のがん細胞が所定の抗がん剤に対して耐性を獲得したか否かを判定した結果が含まれ、
前記入力情報取得部は、予測する対象とする対象者に関する前記状態情報および前記対象者から採取された細胞のオミクス情報を含む対象者情報を、前記入力情報として取得し、
前記予測部は、前記対象者のがん細胞が所定の抗がん剤に対して耐性を獲得する度合いを予測する、
請求項4に記載の評価システム。 - 前記薬剤有効性情報には、前記被験者のがん細胞が所定の第1抗がん剤に対して耐性を獲得したか否かを判定した結果が含まれ、
前記投与実績情報には、前記被験者のがん細胞に投与した前記第1抗がん剤とは異なる第2抗がん剤が、前記被験者のがん細胞が前記第1抗がん剤に対して耐性を得た後に投与されたものか否かを示す情報が含まれ、
前記入力情報取得部は、予測する対象とする対象者に関する前記状態情報および前記対象者から採取された細胞のオミクス情報を含む対象者情報を、前記入力情報として取得し、
前記予測部は、前記対象者のがん細胞が前記第1抗がん剤に対して耐性を獲得した後において、前記第2抗がん剤が前記対象者のがん細胞に作用する効果を予測する、
請求項4に記載の評価システム。 - 不特定の被験者におけるがんに関する情報である学習データと、前記被験者から採取された細胞に抗がん剤を投与することにより得られる前記抗がん剤の効果に関する情報である教師データとを取得する学習情報取得部と、
前記学習情報取得部により取得された学習データ及び前記教師データの対応関係を、学習モデルに教師あり学習させることにより、抗がん剤を用いた治療に関する予測を行う予測モデルを生成する学習部と、
を備える学習装置。 - 予測する対象とする対象者におけるがんに関する情報である入力情報を取得する入力情報取得部と、
前記入力情報と予測モデルとを用いて、抗がん剤を用いた治療に関する予測を行う予測部と、
を備え、
前記予測モデルは、不特定の被験者におけるがんに関する情報である学習データと、前記被験者から採取された細胞に抗がん剤を投与することにより得られる前記抗がん剤の効果に関する情報である教師データの対応関係を、学習モデルに教師あり学習させることにより生成された、抗がん剤を用いた治療に関する予測を行うモデルである、
予測装置。 - 抗がん効果を評価する評価方法であって、
学習情報取得部が、不特定の被験者におけるがんに関する情報である学習データと、前記被験者から採取された細胞に抗がん剤を投与することにより得られる前記抗がん剤の効果に関する情報である教師データとを取得し、
学習部が、前記学習情報取得部により取得された学習データ及び前記教師データの対応関係を、学習モデルに教師あり学習させることにより、抗がん剤を用いた治療に関する予測を行う予測モデルを生成し、
記憶部が、前記学習部により生成された予測モデルを記憶し、
入力情報取得部が、予測する対象とする対象者におけるがんに関する情報である入力情報を取得し、
予測部が、前記入力情報と前記予測モデルとを用いて、抗がん剤を用いた治療に関する予測を行う、
評価方法。 - コンピュータを、請求項12に記載の学習装置として動作させるためのプログラムであって、前記コンピュータを前記学習装置が備える各部として機能させるためのプログラム。
- コンピュータを、請求項13に記載の予測装置として動作させるためのプログラムであって、前記コンピュータを前記予測装置が備える各部として機能させるためのプログラム。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020113218A JP6810294B1 (ja) | 2020-06-30 | 2020-06-30 | 評価システム、学習装置、予測装置、評価方法、及びプログラム |
JP2020205333A JP2022013583A (ja) | 2020-06-30 | 2020-12-10 | 予測方法 |
PCT/JP2021/024571 WO2022004726A1 (ja) | 2020-06-30 | 2021-06-29 | 評価装置、学習装置、予測装置、評価方法、プログラム、及びコンピュータ読み取り可能な記憶媒体 |
EP21831492.0A EP4174873A4 (en) | 2020-06-30 | 2021-06-29 | EVALUATION DEVICE, LEARNING DEVICE, PREDICTION DEVICE, EVALUATION METHOD, PROGRAM AND COMPUTER READABLE STORAGE MEDIUM |
CN202180042369.7A CN115769310A (zh) | 2020-06-30 | 2021-06-29 | 评价装置、学习装置、预测装置、评价方法、程序以及计算机可读取的存储介质 |
US18/069,509 US20230121965A1 (en) | 2020-06-30 | 2022-12-21 | Evaluation device, learning device, prediction device, evaluation method, program, and computer-readable storage medium |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020113218A JP6810294B1 (ja) | 2020-06-30 | 2020-06-30 | 評価システム、学習装置、予測装置、評価方法、及びプログラム |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020205333A Division JP2022013583A (ja) | 2020-06-30 | 2020-12-10 | 予測方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP6810294B1 JP6810294B1 (ja) | 2021-01-06 |
JP2022011833A true JP2022011833A (ja) | 2022-01-17 |
Family
ID=73992885
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020113218A Active JP6810294B1 (ja) | 2020-06-30 | 2020-06-30 | 評価システム、学習装置、予測装置、評価方法、及びプログラム |
JP2020205333A Pending JP2022013583A (ja) | 2020-06-30 | 2020-12-10 | 予測方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020205333A Pending JP2022013583A (ja) | 2020-06-30 | 2020-12-10 | 予測方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230121965A1 (ja) |
EP (1) | EP4174873A4 (ja) |
JP (2) | JP6810294B1 (ja) |
CN (1) | CN115769310A (ja) |
WO (1) | WO2022004726A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3674706A4 (en) * | 2017-08-21 | 2020-08-12 | Toppan Printing Co., Ltd. | METHODS OF EVALUATING ANTI-CANCER EFFECTIVENESS AND METHODS OF PREDICTING EFFECTIVENESS OF ANTI-CANCER IMMUNOTHERAPY |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017183673A1 (ja) * | 2016-04-19 | 2017-10-26 | 凸版印刷株式会社 | 抗がん剤の評価方法 |
WO2019039452A1 (ja) * | 2017-08-21 | 2019-02-28 | 凸版印刷株式会社 | 抗がん効果の評価方法、及びがん免疫療法の奏効性予測方法 |
WO2019208703A1 (ja) * | 2018-04-26 | 2019-10-31 | 日本電気株式会社 | 情報処理装置、制御方法、及びプログラム |
US20190361006A1 (en) * | 2017-02-08 | 2019-11-28 | Mitra Rxdx, Inc. | Method of predicting clinical outcome of anticancer agents |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2919768C (en) * | 2013-06-28 | 2019-12-03 | Nantomics, Llc | Pathway analysis for identification of diagnostic tests |
JP6733920B2 (ja) | 2019-01-16 | 2020-08-05 | 株式会社エクサウィザーズ | 情報処理装置、表示方法およびプログラム |
-
2020
- 2020-06-30 JP JP2020113218A patent/JP6810294B1/ja active Active
- 2020-12-10 JP JP2020205333A patent/JP2022013583A/ja active Pending
-
2021
- 2021-06-29 WO PCT/JP2021/024571 patent/WO2022004726A1/ja unknown
- 2021-06-29 CN CN202180042369.7A patent/CN115769310A/zh active Pending
- 2021-06-29 EP EP21831492.0A patent/EP4174873A4/en active Pending
-
2022
- 2022-12-21 US US18/069,509 patent/US20230121965A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017183673A1 (ja) * | 2016-04-19 | 2017-10-26 | 凸版印刷株式会社 | 抗がん剤の評価方法 |
US20190361006A1 (en) * | 2017-02-08 | 2019-11-28 | Mitra Rxdx, Inc. | Method of predicting clinical outcome of anticancer agents |
WO2019039452A1 (ja) * | 2017-08-21 | 2019-02-28 | 凸版印刷株式会社 | 抗がん効果の評価方法、及びがん免疫療法の奏効性予測方法 |
WO2019208703A1 (ja) * | 2018-04-26 | 2019-10-31 | 日本電気株式会社 | 情報処理装置、制御方法、及びプログラム |
Also Published As
Publication number | Publication date |
---|---|
CN115769310A (zh) | 2023-03-07 |
WO2022004726A1 (ja) | 2022-01-06 |
US20230121965A1 (en) | 2023-04-20 |
EP4174873A4 (en) | 2023-12-27 |
EP4174873A1 (en) | 2023-05-03 |
JP2022013583A (ja) | 2022-01-18 |
JP6810294B1 (ja) | 2021-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11705220B2 (en) | Systems and methods for identifying cancer treatments from normalized biomarker scores | |
Davidson et al. | Single-cell RNA sequencing reveals a dynamic stromal niche that supports tumor growth | |
Lee et al. | Genetically engineered mouse models of pancreatic cancer: the KPC model (LSL‐KrasG12D/+; LSL‐Trp53R172H/+; Pdx‐1‐Cre), its variants, and their application in immuno‐oncology drug discovery | |
WO2016209865A1 (en) | Non-hla matched humanized nsg mouse model with patient-derived xenograft | |
JP7452609B2 (ja) | 抗がん効果の評価方法、及びがん免疫療法の奏効性予測方法 | |
Klinge et al. | CD68+ macrophages as crucial components of the foreign body reaction demonstrate an unconventional pattern of functional markers quantified by analysis with double fluorescence staining | |
Gottschlich et al. | Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia | |
US20230121965A1 (en) | Evaluation device, learning device, prediction device, evaluation method, program, and computer-readable storage medium | |
Witherel et al. | Host–biomaterial interactions in Zebrafish | |
Epps et al. | Re-programming immunosurveillance in persistent non-infectious ocular inflammation | |
JP2021093927A (ja) | 細胞構造体及びその使用 | |
Zhang et al. | RETRACTED: Inhibition of interleukin-1β plays a protective role in Alzheimer’s disease by promoting microRNA-9-5p and downregulating targeting protein for xenopus kinesin-like protein 2 | |
Clerkin | Preclinical interrogation of novel Immunotherapy treatment strategies in Glioblastoma (GBM) using a novel clinically relevant disease model | |
Chidomere et al. | Bench to Bedside: Modelling Inflammatory Arthritis | |
Roulin et al. | Integrative Study of a High-Grade B-Cell Lymphoma Cohort of 45 Patients: A Single Institution Real Life Study | |
Keck et al. | Achieving Relevant Preclinical Characterization of CAR T Cell Therapies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200630 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20200630 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20200715 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20200813 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200813 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201028 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201110 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201210 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6810294 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |